Marcella Ruddy Sells 10,000 Shares of Tectonic Therapeutic (NASDAQ:TECX) Stock

Tectonic Therapeutic, Inc. (NASDAQ:TECX) insider Marcella Ruddy sold 10,000 shares of the stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the transaction, the insider owned 69,747 shares of the company’s stock, valued at approximately $2,092,410. This trade represents a 12.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Tectonic Therapeutic Price Performance

Shares of Tectonic Therapeutic stock opened at $33.24 on Wednesday. The firm has a market cap of $624.25 million, a price-to-earnings ratio of -8.21 and a beta of 3.76. The stock’s 50-day moving average is $22.29 and its 200-day moving average is $19.85. Tectonic Therapeutic, Inc. has a one year low of $13.70 and a one year high of $36.03.

Tectonic Therapeutic (NASDAQ:TECX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.08. On average, equities analysts expect that Tectonic Therapeutic, Inc. will post -8.31 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TECX. Truist Financial lowered their price objective on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Lifesci Capital upgraded shares of Tectonic Therapeutic to a “strong-buy” rating in a report on Thursday, February 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tectonic Therapeutic in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Tectonic Therapeutic has a consensus rating of “Moderate Buy” and an average price target of $81.50.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Millennium Management LLC increased its position in shares of Tectonic Therapeutic by 726.4% during the 1st quarter. Millennium Management LLC now owns 237,938 shares of the company’s stock worth $4,214,000 after purchasing an additional 209,145 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Tectonic Therapeutic by 331.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 104,793 shares of the company’s stock valued at $1,856,000 after buying an additional 80,483 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Tectonic Therapeutic by 58.7% in the 1st quarter. Jane Street Group LLC now owns 47,145 shares of the company’s stock valued at $835,000 after buying an additional 17,443 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Tectonic Therapeutic by 3.1% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 35,708 shares of the company’s stock valued at $710,000 after buying an additional 1,063 shares in the last quarter. Finally, Monaco Asset Management SAM bought a new position in shares of Tectonic Therapeutic in the second quarter valued at $209,000. 62.63% of the stock is currently owned by institutional investors.

Trending Headlines about Tectonic Therapeutic

Here are the key news stories impacting Tectonic Therapeutic this week:

• Positive Sentiment: Analysts remain constructive — the consensus rating is “Moderate Buy” with a meaningful average price target that implies material upside versus current levels. Analyst Coverage
• Positive Sentiment: Strong technical momentum — coverage noting a 96 relative-strength (RS) rating signals market leadership and can attract momentum/quant flows. RS Rating Article
• Positive Sentiment: Recent earnings slightly beat estimates — the company reported an EPS beat for the last quarter, which supports the growth thesis versus purely speculative biotech peers. Earnings & Stock Data
• Positive Sentiment: Institutional accumulation — recent filings and commentary indicate increased positions from several funds, suggesting professional investor demand that can provide a bid under the stock. Institutional Activity
• Neutral Sentiment: Leadership transition announced — the company named a new chair and outlined an executive transition; impact depends on the incoming chair’s strategy and communication of near-term priorities. Leadership Transition
• Negative Sentiment: Large insider sale by Marcella K. Ruddy — sold 10,000 shares at roughly $30 (≈12.5% reduction in her stake). The size and disclosure of this sale is likely a principal reason for downward pressure on the stock today. Ruddy SEC Filing
• Negative Sentiment: Insider selling by Peter McNamara — sold 6,262 shares at ~$30.17 (≈10.2% reduction), plus earlier small sales earlier in the week; adds to supply and negative sentiment. Mcnamara SEC Filing

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.